keyword
Keywords Liver, liver transplantation, ...

Liver, liver transplantation, hepatocellular carcinoma, hepatectomy, cholangiocarcinoma

https://read.qxmd.com/read/38343605/update-on-the-diagnosis-and-treatment-of-combined-hepatocellular-cholangiocarcinoma
#1
REVIEW
Kai-Jian Chu, Yoshikuni Kawaguchi, Han Wang, Xiao-Qing Jiang, Kiyoshi Hasegawa
Combined hepatocellular-cholangiocarcinoma (cHCC-CCA) is a unique type of liver tumor that contains both hepatocellular carcinoma and cholangiocarcinoma components within a single tumor. The fifth edition of the World Health Organization classification provides a definition and diagnostic criteria for cHCC-CCA. However, the heterogeneous histomorphology and presentation resulting from variation of the proportion of each component poses challenges for clinical diagnosis and treatment. A diagnosis of cHCC-CCA may be suggested by the synchronous elevation of serum tumor markers for hepatocellular carcinoma and cholangiocarcinoma, a mixed enhancement pattern on imaging, and a discrepancy between the elevation of tumor marker and the imaging enhancement pattern...
February 28, 2024: Journal of Clinical and Translational Hepatology
https://read.qxmd.com/read/38128340/advances-and-considerations-in-the-use-of-immunotherapies-for-primary-hepato-biliary-malignancies
#2
REVIEW
Leva Gorji, Zachary J Brown, Timothy M Pawlik
Hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA) comprise the two most common primary liver malignancies. Curative treatment options often include hepatectomy or liver transplantation; however, many patients present with advanced disease that is not amenable to surgical management. In turn, many patients are treated with systemic or targeted therapy. The tumor microenvironment (TME) is a complex network of immune cells and somatic cells, which can foster an environment for disease development and progression, as well as susceptibility and resistance to systemic therapeutic agents...
February 2024: Surgical Oncology
https://read.qxmd.com/read/38084526/combined-hepatocellular-cholangiocarcinoma-in-hepatectomy-specimens-a-clinicopathologic-analysis
#3
JOURNAL ARTICLE
Nayana Patil, Puja Sahai, Archana Rastogi, Namita Sharma, Saggere Muralikrishna Shasthry, Amar Mukund, Shalini Thapar Laroia, Guresh Kumar, Viniyendra Pamecha, Shiv Kumar Sarin
BACKGROUND: Combined hepatocellular-cholangiocarcinoma (cHCC-CCA) is an uncommon form of primary liver carcinoma. It is heterogenous in terms of morphology, immunohistochemistry, radiology, and clinical features; making it a challenging entity for diagnosis. AIMS: The purpose of the present study was to evaluate clinicopathological characteristics of patients with cHCC-CCA. SETTINGS AND DESIGN: Retrospective observational study. MATERIALS AND METHODS: The patients diagnosed with cHCC-CC were identified from hepatic surgical specimens and were evaluated...
2023: Indian Journal of Pathology & Microbiology
https://read.qxmd.com/read/35571416/promising-role-of-liver-transplantation-in-patients-with-combined-hepatocellular-cholangiocarcinoma-a-propensity-score-matching-analysis
#4
JOURNAL ARTICLE
Xiaoyuan Chen, Shiquan Sun, Yiwei Lu, Xiaoli Shi, Ziyi Wang, Xuejiao Chen, Guoyong Han, Jie Zhao, Yun Gao, Xuehao Wang
Background: Combined hepatocellular-cholangiocarcinoma (CHC) is a rare but vital heterogeneous histological subtype of primary liver cancer (PLC) with no standardized treatment strategy. This study aimed to preliminarily investigate the role of liver transplantation (LT) in CHC and develop a novel risk scoring model (RSM) to evaluate the benefits of transplantation. Methods: The study cohort was taken from the Surveillance, Epidemiology, and End Results database...
April 2022: Annals of Translational Medicine
https://read.qxmd.com/read/35053523/treatment-of-intrahepatic-cholangiocarcinoma-a-multidisciplinary-approach
#5
REVIEW
Felix Krenzien, Nora Nevermann, Alina Krombholz, Christian Benzing, Philipp Haber, Uli Fehrenbach, Georg Lurje, Uwe Pelzer, Johann Pratschke, Moritz Schmelzle, Wenzel Schöning
Intrahepatic cholangiocarcinoma (iCC) is distinguished as an entity from perihilar and distal cholangiocarcinoma and gallbladder carcinoma. Recently, molecular profiling and histopathological features have allowed further classification. Due to the frequent delay in diagnosis, the prognosis for iCC remains poor despite major technical advances and multimodal therapeutic approaches. Liver resection represents the therapeutic backbone and only curative treatment option, with the functional residual capacity of the liver and oncologic radicality being deciding factors for postoperative and long-term oncological outcome...
January 12, 2022: Cancers
https://read.qxmd.com/read/34925507/morbidity-prognostic-factors-and-competing-risk-nomogram-for-combined-hepatocellular-cholangiocarcinoma
#6
JOURNAL ARTICLE
Xiaoyuan Chen, Yiwei Lu, Xiaoli Shi, Xuejiao Chen, Dawei Rong, Guoyong Han, Long Zhang, Chuangye Ni, Jie Zhao, Yun Gao, Xuehao Wang
Background: Combined hepatocellular-cholangiocarcinoma (CHC) is a rare and heterogeneous histological subtype of primary liver cancer, which is still poorly understood. This study aimed to describe the epidemiological and clinical features, investigate the prognostic indicators, and develop a competing risk nomogram for CHC. Methods: The study cohort was taken from the Surveillance, Epidemiology, and End Results database. The annual percent change (APC) in incidence was calculated using the joinpoint regression...
2021: Journal of Oncology
https://read.qxmd.com/read/34584804/primary-neuroendocrine-tumor-of-the-liver-with-papillary-features-in-a-multivisceral-transplant-patient
#7
Jaffar Khan, Lin Jingmei
Primary neuroendocrine tumors (NETs) of the liver are rare and difficult to distinguish from other liver tumors such as cholangiocarcinoma and hepatocellular carcinoma. The patient was initially diagnosed with a NET of the liver in 2007. However, the origin of the cancer was not clear, that is, whether it was primary or originated from the gastrointestinal tract. Although the patient underwent partial hepatectomy, he suffered hepatic artery injury, resulting in biliary strictures. The patient eventually became untreatable and developed cirrhosis, a frozen abdomen...
August 2021: Curēus
https://read.qxmd.com/read/34226385/setting-up-a-division-of-hbp-surgery-at-a-local-university-hospital
#8
Yang Won Nah
Dear members and colleagues, it is my great honor being the president of our society, Korean Association of HBP Surgery over the last year and being here to present my talk today as well. Ulsan University Hospital (UUH) was designated as a university hospital in March 1997 but was not gaining the trust of the local people at the time. It had been a general hospital and not specialized in the care of malignancy or organ transplantation. When I was appointed to the UUH in 2001, I thought about how to gain the trust of the local people...
June 30, 2021: Annals of Hepato-Biliary-Pancreatic Surgery
https://read.qxmd.com/read/34135153/an-approach-to-grossing-of-hepatectomy-specimens
#9
REVIEW
Archana Rastogi
Liver resections are performed for acute and chronic end stage liver failure, primary and secondary liver malignancies as well as for several other neoplastic and non-neoplastic conditions. Hepatectomy specimens can be total, partial, or wedge resections. These specimens are relatively rare and complex. Meticulous handling, orientation, dissection, margin assessment, and reporting as per the latest guidelines, often require a multidisciplinary approach. This article discusses the approach to grossing of hepatectomy specimens, and the most important macroscopic considerations for specific conditions...
June 2021: Indian Journal of Pathology & Microbiology
https://read.qxmd.com/read/33412628/-surgical-treatment-of-primary-liver-cancer-a-report-of-10-966-cases
#10
JOURNAL ARTICLE
Y X Xia, F Zhang, X C Li, L B Kong, H Zhang, D H Li, F Cheng, L Y Pu, C Y Zhang, X F Qian, P Wang, K Wang, Z S Wu, L Lyu, J H Rao, X F Wu, A H Yao, W Y Shao, Y Fan, W You, X Z Dai, J J Qin, M Y Li, Q Zhu, X H Wang
Objective: To summarize the experience of surgical treatment of primary liver cancer. Methods: The clinical data of 10 966 surgically managed cases with primary liver cancer, from January 1986 to December 2019 at Hepatobiliary Center, the First Affiliated Hospital of Nanjing Medical University, were retrospectively analyzed. The life table method was used to calculate the survival rate and postoperative recurrence rate. Log-rank test was used to compare the survival process of different groups, and the Cox regression model was used for multivariate analysis...
January 1, 2021: Zhonghua Wai Ke za Zhi [Chinese Journal of Surgery]
https://read.qxmd.com/read/33073719/clinical-features-and-diagnostic-imaging-of-cholangiolocellular-carcinoma-compared-with-other-primary-liver-cancers-a-surgical-perspective
#11
JOURNAL ARTICLE
Hiroyuki Takamura, Ryousuke Gabata, Yoshinao Obatake, Shinichi Nakanuma, Hironori Hayashi, Kazuto Kozaka, Motoko Sasaki, Mitsuyoshi Okazaki, Takahisa Yamaguchi, Hiroyuki Shimbashi, Shiro Terai, Koichi Okamoto, Isamu Makino, Jun Kinoshita, Keishi Nakamura, Tomoharu Miyashita, Hidehiro Tajima, Itasu Ninomiya, Sachio Fushida, Azusa Kitao, Masaaki Kitahara, Kuniaki Arai, Taro Yamashita, Tatsuya Yamashita, Hiroko Ikeda, Yasunori Satoh, Kenichi Harada, Syuichi Kaneko, Toshihumi Gabata, Tateo Kosaka, Tetsuo Ohta
BACKGROUND AND OBJECTIVES: Although cholangiolocellular carcinoma is considered a combined hepatocellular and cholangiocarcinoma, we feel that this classification is not appropriate. Therefore, we compared the diagnostic imaging findings, surgical prognosis, and pathological features of cholangiolocellular carcinoma with those of other combined hepatocellular and cholangiocarcinoma subtypes, hepatocellular carcinoma, and cholangiocarcinoma. METHODS: The study patients included 7 with classical type combined hepatocellular and cholangiocarcinoma; 8 with stem cell feature, intermediate type combined hepatocellular and cholangiocarcinoma; 13 with cholangiolocellular carcinoma; 58 with cholangiocarcinoma; and 359 with hepatocellular carcinoma...
January 2020: Technology in Cancer Research & Treatment
https://read.qxmd.com/read/32753331/combined-hepatocellular-cholangiocarcinoma-an-update-on-epidemiology-classification-diagnosis-and-management
#12
JOURNAL ARTICLE
Dimitrios Schizas, Aikaterini Mastoraki, Eleni Routsi, Michail Papapanou, Dimitrios Tsapralis, Pantelis Vassiliu, Konstantinos Toutouzas, Evangelos Felekouras
BACKGROUND: Combined hepatocellular-cholangiocarcinoma (CHC) is a rare subtype of primary hepatic malignancies, with variably reported incidence between 0.4%-14.2% of primary liver cancer cases. This study aimed to systematically review the epidemiological, clinicopathological, diagnostic and therapeutic data for this rare entity. DATA SOURCES: We reviewed the literature of diagnostic approach of CHC with special reference to its clinical, molecular and histopathological characteristics...
December 2020: Hepatobiliary & Pancreatic Diseases International: HBPD INT
https://read.qxmd.com/read/32657940/transferability-of-liver-transplantation-experience-to-complex-liver-resection-for-locally-advanced-hepatobiliary-malignancy-lessons-learnt-from-3-decades-of-single-center-experience
#13
JOURNAL ARTICLE
Albert C Y Chan, Kenneth S H Chok, Jeff Dai, Simon H Y Tsang, Tan To Cheung, Ronnie Poon, S T Fan, C M Lo
OBJECTIVE: To study the impact of LT experience on the outcome of CLR for locally advanced hepatobiliary malignancy SUMMARY OF BACKGROUND DATA:: Despite evolution in LT knowledge and surgical techniques in the past decades, there is yet data to evaluate the significance of LT experience in performing CLR. METHODS: Postoperative outcome after CLR between 1995 and 2019 were reviewed and correlated with LT experience in a single center with both LT and CLR service...
July 9, 2020: Annals of Surgery
https://read.qxmd.com/read/32016491/-surgical-treatment-of-hepatic-tumors-liver-resection-and-transplantation
#14
REVIEW
H Lang, S Heinrich, F Bartsch, F Hüttl, J Baumgart, J Mittler
The most frequent primary hepatic malignancies are hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (intrahepatic cholangiocellular adenocarcinoma [iCCA]). For HCC in cirrhosis, liver transplantation offers the advantage of a complete hepatectomy radically removing all tumorous tissue along with the surrounding cirrhotic parenchyma, which is otherwise associated with a very high risk of recurrence. For HCC in non-cirrhotic livers and iCCA, liver resection is the treatment of choice. Nowadays, even extended resections can be performed with low mortality in experienced centers...
February 2020: Der Internist
https://read.qxmd.com/read/31954498/liver-resection-and-transplantation-for-intrahepatic-cholangiocarcinoma
#15
REVIEW
Vincenzo Mazzaferro, Andre Gorgen, Sasan Roayaie, Michele Droz Dit Busset, Gonzalo Sapisochin
The incidence of intrahepatic cholangiocarcinoma (iCCA) is increasing worldwide. Although several advances have been made in the past decades to better understand this complex malignancy and to develop new treatment strategies, the prognosis of iCCA remains dismal. Liver resection (LR) is the mainstay of treatment but only a minority of patients are amenable to surgery. In most cases, patients with iCCA will require a major hepatectomy for complete resection of the tumour. This may be contraindicated or increase the surgical burden in patients with chronic liver disease and small remnant liver volume...
February 2020: Journal of Hepatology
https://read.qxmd.com/read/30363713/resection-for-intrahepatic-cholangiocellular-cancer-new-advances
#16
REVIEW
Daniel R Waisberg, Rafael S Pinheiro, Lucas S Nacif, Vinicius Rocha-Santos, Rodrigo B Martino, Rubens M Arantes, Liliana Ducatti, Quirino Lai, Wellington Andraus, Luiz C D'Albuquerque
Intrahepatic cholangiocarcinoma (ICC) is the second most prevalent primary liver neoplasm after hepatocellular carcinoma (HCC), corresponding to 10% to 15% of cases. Pathologies that cause chronic biliary inflammation and bile stasis are known predisposing factors for development of ICC. The incidence and cancer-related mortality of ICC is increasing worldwide. Most patients remain asymptomatic until advance stage, commonly presenting with a liver mass incidentally diagnosed. The only potentially curative treatment available for ICC is surgical resection...
2018: Translational Gastroenterology and Hepatology
https://read.qxmd.com/read/30249173/safety-and-efficacy-of-inferior-vena-cava-reconstruction-during-hepatic-resection
#17
JOURNAL ARTICLE
M Papamichail, K Marmagkiolis, M Pizanias, C Koutserimpas, N Heaton
BACKGROUND AND AIMS: Patients with liver tumors involving the inferior vena cava have a poor outcome without surgery. Liver resection en bloc with inferior vena cava resection and reconstruction is now performed in many centers. The purpose of this study is to investigate the safety and efficacy of inferior vena cava reconstruction during hepatic resection. MATERIALS AND METHODS: A review of 12 centers reporting 240 patients with combined hepatectomy and inferior vena cava resection and reconstruction for malignant tumors was performed...
September 24, 2018: Scandinavian Journal of Surgery: SJS
https://read.qxmd.com/read/29327594/liver-resection-and-surgical-strategies-for-management-of-primary-liver-cancer
#18
REVIEW
Sonia T Orcutt, Daniel A Anaya
Primary liver cancer-including hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC)-incidence is increasing and is an important source of cancer-related mortality worldwide. Management of these cancers, even when localized, is challenging due to the association with underlying liver disease and the complex anatomy of the liver. Although for ICC, surgical resection provides the only potential cure, for HCC, the risks and benefits of the multiple curative intent options must be considered to individualize treatment based upon tumor factors, baseline liver function, and the functional status of the patient...
January 2018: Cancer Control: Journal of the Moffitt Cancer Center
https://read.qxmd.com/read/29323061/accuracy-of-vascular-invasion-reporting-in-hepatocellular-carcinoma-before-and-after-implementation-of-subspecialty-surgical-pathology-sign-out
#19
JOURNAL ARTICLE
Aaron R Huber, Raul S Gonzalez, Mark S Orloff, Christopher T Barry, Christa L Whitney-Miller
CONTEXT: Liver cancers (including hepatocellular carcinoma [HCC] and cholangiocarcinoma) are the fifth most common cause of cancer death. The most powerful independent histologic predictor of overall survival after transplantation for HCC is the presence of microscopic vascular invasion (VI). AIMS: Given that VI is known to have somewhat high interobserver variability in both HCC and other tumors, we hypothesized that pathologists with special interest and training in liver pathology would be more likely to identify and report VI in HCC than would general surgical pathologists...
October 2017: Indian Journal of Pathology & Microbiology
https://read.qxmd.com/read/28503555/surgical-options-for-intrahepatic-cholangiocarcinoma
#20
REVIEW
Kui Wang, Han Zhang, Yong Xia, Jian Liu, Feng Shen
Intrahepatic cholangiocarcinoma (ICC) is the second most common primary liver cancer, accounting for 10-15% of primary hepatic malignancy. The incidence and cancer-related mortality of ICC continue to increase worldwide. At present, hepatectomy is still the most effective treatment for ICC patients to achieve long-term survival, although its overall efficacy may not be as good as that for patients with hepatocellular carcinoma (HCC) due to the unique pathogenesis and clinical-pathological profiles of ICC. Viral infection, lithiasis and metabolic factors may all be associated with the pathogenesis of ICC...
April 2017: Hepatobiliary Surgery and Nutrition
keyword
keyword
82661
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.